Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, which together outline its clinical-stage oncology activities, financial position, and material company announcements related to the Alpha DaRT® platform.
Form 6-K filings referenced in the available data include interim consolidated financial statements, operating and financial reviews, and press releases covering topics such as clinical trial updates, investor conference participation, and corporate developments. For example, a 6-K dated August 11, 2025 attaches interim consolidated financial statements as of June 30, 2025 and an operating and financial review, and incorporates these documents by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8. Other 6-Ks furnish press releases about clinical milestones, including treatment of the first patient in a U.S. multi-center pancreatic cancer trial.
Through these filings, investors can review Alpha Tau’s reported research and development expenses, marketing and general and administrative costs, net loss figures, and balance sheet data, as well as narrative discussion of factors that may affect its business. The company’s forward-looking statements sections list risks such as the need for regulatory approvals for Alpha DaRT, limited operating history, ongoing losses, funding requirements, clinical trial uncertainties, and compliance with Nasdaq listing standards and other regulations.
On Stock Titan, SEC filings for Alpha Tau can be viewed alongside AI-powered tools that summarize lengthy documents and highlight key sections, helping readers interpret interim financial statements, risk factor discussions, and exhibit lists. Users interested in DRTS and DRTSW can use this page to track the company’s furnished 6-K reports, annual 20-F filings, and related disclosures that document Alpha Tau’s clinical-stage progress and capital markets activity.
Alpha Tau Medical reported a larger net loss for 2025 while advancing its Alpha DaRT cancer therapy and strengthening its balance sheet. The company posted a 2025 net loss of $42.6 million, or $0.53 per share, compared with a $31.8 million loss, or $0.45 per share, in 2024, driven mainly by higher research and development and general and administrative costs.
R&D expenses rose to $32.1 million from $27.0 million, and G&A increased to $8.4 million from $6.7 million, while marketing expenses declined slightly. Despite the wider loss, cash, cash equivalents, short-term deposits and restricted deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million a year earlier, supporting ongoing trials and commercial preparations. Recent milestones include Japanese marketing approval for Alpha DaRT, a fifth parallel U.S. trial approval, first brain cancer treatment using Alpha DaRT, and progress across pancreatic and glioblastoma studies.
Alpha Tau Medical Ltd. files its annual Form 20‑F as a clinical‑stage oncology company developing its Alpha DaRT local alpha‑radiation technology for solid tumors. The company has no product revenue and reported net losses of
As of that date, Alpha Tau had 88,009,737 ordinary shares outstanding. In April 2025 it sold 14,110,121 ordinary shares to Oramed Ltd. at
DRTS submitted a Form 144 notice identifying a proposed sale of 10,000 ordinary shares through Oppenheimer & Co. Inc.
The filing also lists 87,500 restricted stock units dated
Alpha Tau Medical Ltd. reported that Japan’s Ministry of Health, Labour and Welfare has granted Shonin marketing approval for its Alpha DaRT® therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. This is the first regulatory approval for the Alpha DaRT platform outside Israel.
As a condition of approval, the company will run a post-market surveillance study in Japan, enrolling 66 patients across five leading clinical centers to further evaluate safety and clinical performance. Alpha Tau and its partner HekaBio are preparing for launch and plan discussions with Japanese authorities about potential reimbursement and additional clinical studies in other tumor types.
An insider has filed a notice of proposed sale under Rule 144 to sell 87,010 ordinary shares through Oppenheimer & Co. Inc. on or about 02/02/2026, with the shares listed on Nasdaq. The aggregate market value of this planned sale is stated as
The insider, identified as Gat Amnon, previously sold ordinary shares of the same issuer during the past three months. These earlier sales were 16,000 shares on
Alpha Tau Medical Ltd. provides a detailed update on its Alpha DaRT cancer therapy program, highlighting an expectedly active 2026 with multiple clinical and regulatory milestones. The company now has five concurrently approved trials in the U.S., alongside studies in Europe, Japan and Israel.
Management targets completion of patient recruitment in the IMPACT pancreatic cancer study by the end of Q1 2026, with initial results around year end. A U.S. glioblastoma trial has begun dosing, with plans to enroll ten patients and aim for initial data around the end of 2026, subject to safety review and site expansion.
The company anticipates a regulatory decision in Japan for recurrent head and neck cancer and is progressing its ReSTART pivotal skin cancer trial, expecting to complete enrollment this quarter and finish Modular PMA submission to the FDA toward year end. Alpha Tau continues to ramp manufacturing in Israel and the U.S., build out its New Hampshire facility, invest in automation, and expand intellectual property with dozens of new patent applications and grants while describing its cash burn as stable.
Alpha Tau Medical Ltd. furnished a Form 6-K to provide investors with a press release dated September 2, 2025. The release, attached as Exhibit 99.1, announces that Alpha Tau successfully treated the first patient in its U.S. multi-center pancreatic cancer clinical trial.
The Form 6-K specifies that the information, including the exhibit, is furnished rather than filed under U.S. securities laws, which affects how it is incorporated into other regulatory documents.
Alpha Tau Medical Ltd. furnished a Form 6-K to provide investors with a press release dated August 27, 2025. The release, attached as Exhibit 99.1, announces that the company will participate in five investor conferences scheduled for September.
The furnished information, including the press release, is not deemed filed for liability purposes under the U.S. Exchange Act and is not automatically incorporated by reference into other U.S. securities filings unless specifically referenced there.
Alpha Tau Medical Ltd. filed a Form 6-K furnishing its interim consolidated financial statements as of June 30, 2025 and an operating and financial review for the six months ended June 30, 2025. These documents, plus an August 11, 2025 press release, are incorporated by reference into multiple existing Form F-3 and Form S-8 registration statements.